Answers are grounded in this paper and cite their sources.
CAR-T cell therapy has been heralded as a breakthrough in the field of immunotherapy, but to date, this success has been limited to hematological malignancies. By harnessing the chemokine system and taking into consideration the chemokine expression profile in the tumor microenvironment, CAR-T cells may be homed into tumors to facilitate direct tumor cell cytolysis and overcome a major hurdle in generating effective CAR-T cell responses to solid cancers.
No takes yet. Share an insight, caveat, or question.
Foeng et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: